Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.
- Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.
- The positive GLP toxicology results represent a key milestone for Alzamend as we continue to advance our proprietary pipeline.
- We believe AL002 could potentially reverse the effects of Alzheimers disease.
- A five-dose GLP study with AL002-sensitized cells was completed using a transgenic (or genetically modified) mouse model of Alzheimers disease to investigate the tolerability of AL002.